Lakefront Biotherapeutics (LKFT) Change in Account Payables (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has 5 years of Change in Account Payables data on file, last reported at $27.6 million in Q1 2020.

• Change in Account Payables for Q1 2020 came in at $27.6 million, up 2393.67% year-over-year; the trailing twelve-month figure through Mar 2020 was -$196.3 million (down 518.24% YoY), and the FY2025 annual result was $39.4 million, up 168.94% from the prior year.
• Change in Account Payables climbed to $27.6 million in Q1 2020 per LKFT's latest filing, from -$165.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $27.6 million in Q1 2020 and troughed at -$165.2 million in Q4 2019.
• A 5-year average of -$10.6 million and a median of $9.3 million in 2018 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2018 and 2020: Change in Account Payables slumped 540.19% in 2018, then surged 2393.67% in 2020.
• A 5-year view of Change in Account Payables shows it stood at -$10.4 million in 2016, then surged by 225.15% to $13.1 million in 2017, then tumbled by 540.19% to -$57.5 million in 2018, then sank by 187.28% to -$165.2 million in 2019, then surged by 116.69% to $27.6 million in 2020.
• Business Quant data shows LKFT's Change in Account Payables at $27.6 million in Q1 2020, -$165.2 million in Q4 2019, and -$1.2 million in Q1 2019.